170 related articles for article (PubMed ID: 31714258)
1. c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract.
Pors J; Ho J; Prentice L; Thompson E; Cochrane D; Gibbard E; Huntsman D; Gilks B; Hoang LN
Am J Surg Pathol; 2020 Apr; 44(4):495-502. PubMed ID: 31714258
[TBL] [Abstract][Full Text] [Related]
2. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
[TBL] [Abstract][Full Text] [Related]
3. Targeted Genomic Profiling of Female Adnexal Tumors of Probable Wolffian Origin (FATWO).
Mirkovic J; Dong F; Sholl LM; Garcia E; Lindeman N; MacConaill L; Crum CP; Nucci MR; McCluggage WG; Howitt BE
Int J Gynecol Pathol; 2019 Nov; 38(6):543-551. PubMed ID: 30134342
[TBL] [Abstract][Full Text] [Related]
4. Extrauterine Mesonephric-like Neoplasms: Expanding the Morphologic Spectrum.
Deolet E; Arora I; Van Dorpe J; Van der Meulen J; Desai S; Van Roy N; Kaur B; Van de Vijver K; McCluggage WG
Am J Surg Pathol; 2022 Jan; 46(1):124-133. PubMed ID: 34183523
[TBL] [Abstract][Full Text] [Related]
5. Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract.
Mirkovic J; Sholl LM; Garcia E; Lindeman N; MacConaill L; Hirsch M; Dal Cin P; Gorman M; Barletta JA; Nucci MR; McCluggage WG; Howitt BE
Mod Pathol; 2015 Nov; 28(11):1504-14. PubMed ID: 26336887
[TBL] [Abstract][Full Text] [Related]
6. Female adnexal tumor of probable wolffian origin: morphological, immunohistochemical, and ultrastructural study with c-kit gene analysis.
Harada O; Ota H; Takagi K; Matsuura H; Hidaka E; Nakayama J
Pathol Int; 2006 Feb; 56(2):95-100. PubMed ID: 16445822
[TBL] [Abstract][Full Text] [Related]
7. Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases.
da Silva EM; Fix DJ; Sebastiao APM; Selenica P; Ferrando L; Kim SH; Stylianou A; Da Cruz Paula A; Pareja F; Smith ES; Zehir A; Konner JA; Cadoo K; Reis-Filho JS; Abu-Rustum NR; Mueller JJ; Weigelt B; Park KJ
Mod Pathol; 2021 Aug; 34(8):1570-1587. PubMed ID: 33772212
[TBL] [Abstract][Full Text] [Related]
8. GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract.
Howitt BE; Emori MM; Drapkin R; Gaspar C; Barletta JA; Nucci MR; McCluggage WG; Oliva E; Hirsch MS
Am J Surg Pathol; 2015 Oct; 39(10):1411-9. PubMed ID: 26135559
[TBL] [Abstract][Full Text] [Related]
9. Mutation analysis of CTNNB1 gene and the ras pathway genes KRAS, NRAS, BRAF, and PIK3CA in eyelid sebaceous carcinomas.
Kwon MJ; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY
Pathol Res Pract; 2017 Jun; 213(6):654-658. PubMed ID: 28551389
[TBL] [Abstract][Full Text] [Related]
10. KRAS, EGFR, PDGFR-α, KIT and COX-2 status in carcinoma showing thymus-like elements (CASTLE).
Veits L; Schupfner R; Hufnagel P; Penzel R; Freitag J; Ströbel P; Kern MA; Schröder S; Neuhold N; Schmid KW; Schirmacher P; Hartmann A; Rieker RJ
Diagn Pathol; 2014 Jun; 9():116. PubMed ID: 24934485
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
[TBL] [Abstract][Full Text] [Related]
12. Female Adnexal Tumors of Probable Wolffian Origin (FATWO): A Case Series With Next-Generation Sequencing Mutation Analysis.
Cossu A; Casula M; Paliogiannis P; Tanda F; Palomba G; Sini MC; Pisano M; Doneddu V; Palmieri G
Int J Gynecol Pathol; 2017 Nov; 36(6):575-581. PubMed ID: 28463911
[TBL] [Abstract][Full Text] [Related]
13. Mesonephric proliferations of the female genital tract.
Howitt BE; Nucci MR
Pathology; 2018 Feb; 50(2):141-150. PubMed ID: 29269124
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract.
Pors J; Cheng A; Leo JM; Kinloch MA; Gilks B; Hoang L
Am J Surg Pathol; 2018 Dec; 42(12):1596-1606. PubMed ID: 30148742
[TBL] [Abstract][Full Text] [Related]
15. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
Growdon WB; Roussel BN; Scialabba VL; Foster R; Dias-Santagata D; Iafrate AJ; Ellisen LW; Tambouret RH; Rueda BR; Borger DR
Gynecol Oncol; 2011 Apr; 121(1):212-7. PubMed ID: 21168197
[TBL] [Abstract][Full Text] [Related]
16. A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
Dias-Santagata D; Lam Q; Bergethon K; Baker GM; Iafrate AJ; Rakheja D; Hoang MP
Mod Pathol; 2011 Jul; 24(7):974-82. PubMed ID: 21423156
[TBL] [Abstract][Full Text] [Related]
17. Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract.
Cai YJ; Ke LF; Zhang WW; Lu JP; Chen YP
BMC Cancer; 2021 Jun; 21(1):677. PubMed ID: 34102999
[TBL] [Abstract][Full Text] [Related]
18. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.
Dieter SM; Heining C; Agaimy A; Huebschmann D; Bonekamp D; Hutter B; Ehrenberg KR; Fröhlich M; Schlesner M; Scholl C; Schlemmer HP; Wolf S; Mavratzas A; Jung CS; Gröschel S; von Kalle C; Eils R; Brors B; Penzel R; Kriegsmann M; Reuss DE; Schirmacher P; Stenzinger A; Federspil PA; Weichert W; Glimm H; Fröhling S
Ann Oncol; 2017 Jan; 28(1):142-148. PubMed ID: 27687311
[TBL] [Abstract][Full Text] [Related]
19. Ovarian Combined Low-grade Serous and Mesonephric-like Adenocarcinoma: Further Evidence for A Mullerian Origin of Mesonephric-like Adenocarcinoma.
McCluggage WG; Vosmikova H; Laco J
Int J Gynecol Pathol; 2020 Jan; 39(1):84-92. PubMed ID: 30575604
[TBL] [Abstract][Full Text] [Related]
20. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
